R&D, PharmaMar, Avenida De los Reyes, 1, Pol. Ind. La Mina-Norte, 28770-Colmenar Viejo, Madrid, Spain.
Departmento de Química, Facultad de Ciencias and Centro de Investigacions Científicas Avanzadas (CICA), Universidade de A Coruña, 15071 A Coruña, Spain.
J Nat Prod. 2022 Apr 22;85(4):1059-1066. doi: 10.1021/acs.jnatprod.1c01179. Epub 2022 Mar 2.
A new macrolide, enigmazole C (), and two additional analogues, enigmazoles E () and D (), were obtained from a new species of the genus as part of an ongoing discovery program at PharmaMar to study cytotoxic substances from marine sources. The structures were fully characterized by cumulative analyses of NMR, IR, and MS spectra, along with density functional theory computational calculations. All three of the new compounds feature an unusual 2,3-dihydro-4-pyran-4-one moiety, but only enigmazoles C () and D () showed cytotoxic activity in the micromolar range against A-549 (lung), HT-29 (colon), MDA-MB-231 (breast), and PSN-1 (pancreas) tumor cells.
一种新的大环内酯类化合物 enigmazole C (),以及另外两种类似物 enigmazoles E ()和 D (),是作为 PharmaMar 公司正在进行的海洋来源细胞毒性物质研究计划的一部分,从一个新的属种中分离得到的。通过对 NMR、IR 和 MS 光谱的累积分析以及密度泛函理论计算,对这些结构进行了全面的表征。这三种新化合物都具有不寻常的 2,3-二氢-4-吡喃-4-酮部分,但只有 enigmazole C ()和 D ()对 A-549(肺)、HT-29(结肠)、MDA-MB-231(乳腺)和 PSN-1(胰腺)肿瘤细胞具有微摩尔范围内的细胞毒性活性。